Editas Medicine Files 8-K with Corporate Updates

Ticker: EDIT · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1650664

Sentiment: neutral

Topics: corporate-governance, filing, financials

TL;DR

Editas Medicine filed an 8-K on Dec 6th, reporting corporate updates and financial docs.

AI Summary

Editas Medicine, Inc. filed an 8-K on December 10, 2024, reporting events as of December 6, 2024. The filing includes amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial statements and exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This 8-K filing indicates potential changes in Editas Medicine's corporate structure or governance, which could impact its operational direction and investor relations.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative news or significant financial events.

Key Numbers

Key Players & Entities

FAQ

What specific amendments were made to Editas Medicine's articles of incorporation or bylaws?

The filing indicates amendments were made, but the specific details of these amendments are not provided in the provided text excerpt.

What is the nature of the Regulation FD disclosure mentioned in the filing?

The filing states there is a Regulation FD disclosure, but the content of this disclosure is not detailed in the provided text.

What financial statements and exhibits are included with this 8-K filing?

The filing lists 'Financial Statements and Exhibits' as an item, but the specific contents are not detailed in the provided text.

When is Editas Medicine's fiscal year end?

Editas Medicine's fiscal year ends on December 31.

What is the primary business of Editas Medicine?

Editas Medicine is in the business of 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.

Filing Stats: 655 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-12-09 19:32:59

Key Financial Figures

Filing Documents

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 6, 2024, the Board of Directors of Editas Medicine, Inc. (the "Company") unanimously adopted Amended and Restated By-Laws of the Company (the "By-Laws"), effective immediately, to clarify the definition of "acting in concert" as used therein, and to make certain other clarifying changes in accordance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The foregoing description of the By-Laws is qualified in its entirety by reference to the full text of the By-Laws, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 9, 2024, the Company issued a press release, titled "Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting," a copy of which is furnished as Exhibit 99.1 hereto. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated By-Laws of the Company 99.1 Press release issued by the Company on December 9, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * This exhibit shall be deemed to be furnished and not filed.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITAS MEDICINE, INC. Date: December 9, 2024 By: /s/ Erick Lucera Erick Lucera Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing